FIRST INDIVIDUALIZED CLINICAL CANCER TRIALS WORLDWIDE WITH

- An mRNA-based individualized cancer vaccine targeting neo-antigens
- An intravenous formulation of an mRNA vaccine
- An mRNA-based individualized vaccine drawn from a warehouse of mRNAs encoding cancer-selective antigens
- A genomics-driven GMP-approved manufacturing process for individual patient-specific therapies
COMPANY OVERVIEW

BioNTech is the largest privately held biopharmaceutical company in Europe. We develop truly individualized and patient-tailored treatments against cancer. Our objective is to transform cancer into a manageable and non-lethal disease by providing treatments from a suite of therapeutic platforms and offering lifelong patient support. We currently have several product candidates in clinical development and have established all of the building blocks necessary in an effort to bring highly potent, tailor-made and individualized cancer therapies to patients.

BioNTech is actively engaged in numerous scientific communities, continuously exchanges scientific findings with international key opinion leaders and maintains numerous collaborations with leading pharmaceutical companies. We are committed to further developing innovative cancer immunotherapies with our partners, while also bringing novel concepts into the clinic and eventually to the market.

A number of publications, including four groundbreaking articles published (2015-2017) in the renowned scientific journal Nature*, and patent applications underpin our scientific success and validate our approach. In order to defend our pioneering efforts, we have developed a strong IP position and patent protection with far more than 100 patent families with over 1,000 national filings, to which we constantly add.

Our Mission: Our daily objective is to pioneer scientific innovations by developing patient-tailored and potent immunotherapies to fight cancer.

Our Vision: Make cancer manageable.

INDIVIDUALIZED MRNA IMMUNOLOGY CONCEPTS – A BIONTECH PLATFORM

BioNTech’s initial product candidates for individualized cancer treatments are developed using the company’s mRNA technology platform. The IVAC® (Individualized Vaccines Against Cancer) platform has enabled the design of immunotherapies targeting cancer mutations and therefore has the potential to be universally applicable across cancer types. Since 2016 the platform has been co-developed with Genentech as Individualized Neoantigen Specific Therapy (iNeST). The approach rapidly enables the design of custom-made therapeutic vaccines for every single patient, tailored to his or her needs as well as to the specific characteristics of the tumor.

WE ARE GROWING AND LOOKING FOR...

... committed scientific professionals who are driven to achieve real advances in medicine. If you share our corporate values of innovation, passion, and “unidar-ity” (the combined aspects of unity and solidarity), and want to work on revolutionary approaches to fight cancer and other diseases, have a look at our career portal.

Quick Facts

<table>
<thead>
<tr>
<th>Employees:</th>
<th>950 Employees</th>
</tr>
</thead>
<tbody>
<tr>
<td>(as of January 2019)</td>
<td></td>
</tr>
<tr>
<td>Corporate Headquarters:</td>
<td>An der Goldgrube 12</td>
</tr>
<tr>
<td></td>
<td>55131 Mainz Germany</td>
</tr>
<tr>
<td>Management Team:</td>
<td>Prof. Dr. Ugur Sahin, Co-Founder &amp; CEO</td>
</tr>
<tr>
<td></td>
<td>Sean Marett, CBO &amp; CCO</td>
</tr>
<tr>
<td></td>
<td>Sierk Poetting, CFO &amp; CCO</td>
</tr>
<tr>
<td></td>
<td>Özlem Türeci, CMO</td>
</tr>
<tr>
<td>Investors:</td>
<td>Strüngmann Family Office, Fidelity, Invus,</td>
</tr>
<tr>
<td></td>
<td>Janus Henderson, MIG Fonds, Redmile Group, Salvia</td>
</tr>
</tbody>
</table>

Key Collaborations

- Genentech: Individualized Neoantigen Specific Therapy (iNeST)
- SANOFI: mRNA cancer immunotherapies
- Genmab: Bispecific antibodies
- Lilly: Novel tumor targets and corresponding T cell receptors
- Bayer: Vaccines for animal health applications
- SIEMENS: Fully automated and digitalized manufacturing facility for cancer immunotherapies
- Pfizer: mRNA-based vaccines to prevent influenza

* 2015 Nature: Mutant MHC II epitopes drive therapeutic immune responses to cancer
* 2016 Nature: Systemic RNA delivery to dendritic cells exploits antiviral defense for cancer immunotherapy
* 2017 Nature Medicine: Elimination of large tumors in mice by mRNA-encoded bispecific antibodies
* 2017 Nature: Personalized RNA mutanome vaccines mobilizes poly-specific therapeutic immunity against cancer